Egrifta SV is administered via a subcutaneous injection, meaning it is injected just beneath the skin. Here’s how you can administer it:

1. Preparation:
   
   
   • Wash your hands thoroughly with soap and water.
     
     
   • Prepare your Egrifta SV injection kit, ensuring that you have all the required materials, including the prefilled syringe.
     
     
   • Make sure the medication is clear and free from any particles. If there is any discoloration, do not use the medication.
     
     
2. Injection Site Selection:
   
   
   • Choose an area on your abdomen that is at least 2 inches away from the belly button. This is where you will inject the medication.
     
     
   • Rotate injection sites to avoid irritation.
     
     
3. Injecting the Medication:
   
   
   • Clean the injection site with alcohol swabs.
     
     
   • Pinch the skin gently and insert the needle at a 90-degree angle.
     
     
   • Inject the medication slowly and steadily, then remove the needle.
     
     
   • Apply light pressure to the site with a cotton ball or gauze.
     
     
4. Post-Injection Care:
   
   
   • Dispose of the syringe in a puncture-resistant container.
     
     

If you experience pain, redness, or swelling at the injection site, apply a cool compress.

Egrifta SV contains tesamorelin, a synthetic peptide that mimics the action of growth hormone-releasing hormone (GHRH). GHRH stimulates the pituitary gland to release growth hormone (GH). The primary action of growth hormone is the regulation of fat metabolism and the increase of lean body mass.

Here’s how Egrifta SV works:

• Growth Hormone Release: By acting as a GHRH analogue, tesamorelin stimulates the body to release growth hormone. This hormone then enters the bloodstream and signals the body to reduce fat deposits, especially visceral (abdominal) fat.
  
  
• Fat Redistribution: The reduction in visceral fat is key, as this type of fat is linked to many health risks, including cardiovascular issues and metabolic disturbances. Tesamorelin helps redistribute this fat away from the abdominal cavity and improves body composition.
  
  
• Increased Lean Mass: As a secondary effect, tesamorelin has been shown to increase lean body mass, such as muscle tissue, which is an important aspect of overall physical health.
  
  

Egrifta SV works gradually over time, with most noticeable effects seen after several months of treatment. However, it requires consistent use to achieve and maintain the desired results.

Like all medications, Egrifta SV can cause side effects, although not everyone will experience them. Some of the common side effects include:

Common Side Effects:

• Injection Site Reactions: Pain, redness, or swelling at the injection site.
  
  
• Headache: Mild to moderate headaches are reported by some patients.
  
  
• Muscle or Joint Pain: Some individuals experience musculoskeletal discomfort.
  
  

Serious Side Effects:

• Hyperglycemia: Egrifta may increase blood sugar levels, particularly in patients with diabetes or insulin resistance. It’s important to monitor glucose levels during treatment.
  
  
• Edema: Some patients may experience swelling in their extremities (hands, feet, or ankles) due to fluid retention.
  
  
• Carpal Tunnel Syndrome: There have been reports of carpal tunnel syndrome, which causes numbness, tingling, and weakness in the hands and wrists.
  
  

Allergic Reactions: Though rare, allergic reactions such as rash, itching, or difficulty breathing may occur. If these occur, seek immediate medical attention.

• Diabetes and Blood Sugar Monitoring: Since Egrifta SV can affect insulin sensitivity, it is important to closely monitor blood glucose levels during treatment. Adjustments to antidiabetic medications may be necessary.
  
  
• Pregnancy and Breastfeeding: Egrifta SV should not be used during pregnancy or while breastfeeding, as its effects on these populations are not well understood.
  
  
• Injection Site Care: Rotating the injection sites is crucial to avoid irritation and lipohypertrophy (abnormal tissue growth at the injection site).
  
  

Pre-existing Conditions: Patients with liver disease, kidney problems, or joint conditions should consult their doctor before using Egrifta SV.

• Insulin: Tesamorelin may alter insulin sensitivity, so patients with diabetes or those on insulin therapy should be closely monitored.
  
  
• Growth Hormone or Other Peptide Hormones: Concomitant use of tesamorelin with other growth hormone treatments or peptides may increase the risk of side effects and should be done under medical supervision.
  
  
• Medications Affecting Blood Sugar: Egrifta can affect glucose metabolism, which might alter the effectiveness of antidiabetic medications. Regular blood sugar monitoring is crucial during treatment.
  
  

Lipodystrophy Treatments: If a patient is already undergoing treatment for lipodystrophy with other medications, interactions may occur. Always inform your doctor about all ongoing treatments.

The recommended starting dose of Egrifta SV is 2 mg injected subcutaneously once a day. The exact duration of treatment depends on individual response, and healthcare providers will adjust the dosage as needed based on the patient’s progress.

Egrifta SV is a prescription-only medication and should be used under the supervision of a healthcare provider. Your doctor will evaluate whether this medication is appropriate for you based on your specific condition and overall health status. Regular follow-up visits are necessary to assess the effectiveness of treatment and monitor for side effects.

1. What is Egrifta SV?
   Egrifta SV is a prescription medication used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

2. How does Egrifta SV work?
   It’s a growth hormone–releasing factor (GRF) analog that stimulates the pituitary gland to secrete growth hormone, which helps reduce visceral abdominal fat.

3. Who is Egrifta SV prescribed for?
   Adults with HIV-associated lipodystrophy who have excess abdominal fat.

4. Is Egrifta SV a cure for HIV or lipodystrophy?
   No, it does not cure HIV or lipodystrophy; it only helps reduce abdominal fat.

5. How is Egrifta SV taken?
   It’s given as a once-daily subcutaneous injection (under the skin).

6. Can Egrifta SV be self-administered?
   Yes, patients are usually trained to inject themselves at home.

7. What are common side effects of Egrifta SV?
   Injection site reactions, rash, itching, muscle pain, and increased blood sugar.

8. Does Egrifta SV affect blood sugar levels?
   Yes, it can raise blood sugar and may increase the risk of diabetes.

9. Can Egrifta SV interact with other medications?
   Yes, especially with drugs metabolized by the liver; always inform your doctor about all medicines you take.

10. Is Egrifta SV safe during pregnancy?
    Its safety in pregnancy is not well established; it should only be used if clearly needed.

11. Can Egrifta SV cause weight loss?
    It reduces visceral abdominal fat, but it is not a weight loss medication.

12. Is Egrifta SV addictive or habit-forming?
    No, it is not considered addictive.

13. How long does it take to see results with Egrifta SV?
    Some patients notice improvements in abdominal fat reduction within 12–26 weeks.

14. Can Egrifta SV be used in children?
    It is not recommended for pediatric use.

15. What should I do if I miss a dose of Egrifta SV?
    Take the missed dose as soon as possible, but skip if it’s almost time for your next dose.

16. Does Egrifta SV require refrigeration?
    Yes, the vials should be stored in the refrigerator until use.

17. How is Egrifta SV different from growth hormone therapy?
    Egrifta SV stimulates the natural release of growth hormone instead of directly supplying it.

18. Can Egrifta SV help reduce fat in areas other than the abdomen?
    Its effect is mainly on visceral abdominal fat; it may not significantly change fat in other areas.

19. Who should not use Egrifta SV?
    People with active cancer, pituitary gland tumors, or known hypersensitivity to the drug.

20. When should I stop using Egrifta SV?
    Only under the guidance of a healthcare provider, especially if serious side effects occur.